The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 300.50
Ask: 303.50
Change: -1.00 (-0.33%)
Spread: 3.00 (0.998%)
Open: 302.00
High: 304.00
Low: 296.50
Prev. Close: 305.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

28 Oct 2014 07:00

RNS Number : 4095V
Synthomer PLC
28 October 2014
 



28th October 2014

 

Synthomer plc

 

Interim Management Statement

 

Synthomer plc ("Synthomer" or "the Group") today issues its Interim Management Statement for the period 1 July to 28 October 2014.

 

Trading

 

At our interim results on August 11th 2014, we reported firmer demand in our European and North America (ENA) segment, particularly in construction. Unfortunately this improved demand trend has not persisted through the third quarter and volumes, excluding business that we deliberately exited in compounds as reported in half one, were down 3% in ENA. Despite this, unit cash margins continued to firm as a result of our active margin management strategy, and year-to-date average margins in ENA are now ahead of the 2013 average. However, on a local currency basis, as at the end of the third quarter, year-to-date operating profit was slightly down on the prior year.

 

In our Asia and Rest of the World (ARW) segment, volumes increased by 1.3% in the quarter. Volumes have been impacted somewhat by our market activities to improve unit cash margins in the nitrile business, where we have made good progress. We remain positive about continuing demand growth in the nitrile latex market.

 

Financial Position

 

The balance sheet remains in a strong position with the net debt / EBITDA ratio at approximately 1x.

 

We completed the purchase of the other 50% of our EKA Synthomer JV in Finland in October from Akzo Nobel for €5 million. The entity has some €6 million of debt at the transaction date which will be consolidated at the year end, meaning year end net debt for the Group will be slightly higher than previous expectations, and is likely to be similar to the mid-year position.

 

Consistent with our capital management policy articulated at the interim results, if excess capital has not been deployed for either bolt-on acquisitions or capital expenditure, at the year end the Board will consider a one-off capital return to shareholders to maintain an efficient balance sheet.

 

Outlook

At current run rates and given the current demand environment in Europe, the Board now expects full year profit-before-tax to be slightly below current consensus1. We are cautious about performance in Europe given recent economic developments, and should this impact demand further than currently anticipated in the fourth quarter, then profit-before-tax is likely to be around the lower end of the current consensus range2.

 

1. Company compiled 2014 consensus PBT: £87.8 million

2. Company compiled 2014 consensus PBT range: £81.3million - £90.3 million

 

  

Enquiries:

 

Adrian Whitfield, Chief Executive Officer

Charles Armitstead / Rebecca Hall

David Blackwood, Chief Financial Officer

Pendomer Communications

Tel: 01279 442791

Tel: 020 3603 5220

 

 

The company will host a conference call for analysts at 8.30am today. Please contact Pendomer Communications on 020 3603 5220 for dial in details.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUBVNRSRARUAA
Date   Source Headline
7th Jun 20124:35 pmRNSDirector/PDMR Shareholding
25th May 201211:00 amRNSDirector Declaration
17th May 201212:22 pmRNSResult of AGM
17th May 201211:00 amRNSDirectorate Change
17th May 20127:00 amRNSInterim Management Statement
14th May 20123:47 pmRNSAnnual Information Update
17th Apr 20129:18 amRNSAnnual Financial Report
3rd Apr 20123:11 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSMarl Site Operations
28th Mar 20125:15 pmRNSHolding(s) in Company
26th Mar 20127:00 amRNSDirector/PDMR Shareholding
23rd Mar 20127:00 amRNSDirectorate Change
19th Mar 20124:10 pmRNSDirector/PDMR Shareholding
16th Mar 20121:48 pmRNSDirector/PDMR Shareholding
16th Mar 20121:46 pmRNSDirector/PDMR Shareholding
16th Mar 20121:09 pmRNSDirector/PDMR Shareholding
14th Mar 20123:52 pmRNSDirector/PDMR Shareholding
14th Mar 20127:00 amRNSFinal Results
11th Jan 20127:00 amRNSTrading Update
9th Jan 201210:24 amRNSDirector/PDMR Shareholding
3rd Jan 20124:51 pmRNSDirector/PDMR Shareholding
1st Dec 20117:00 amRNSDisposal of Pharma Division
25th Nov 20117:00 amRNSDirectorate Change
10th Nov 20117:00 amRNSInterim Management Statement
1st Nov 20113:33 pmRNSHolding(s) in Company
31st Oct 201110:15 amRNSHolding(s) in Company
20th Oct 20112:42 pmRNSHolding(s) in Company
17th Oct 20118:20 amRNSAcquisition
28th Sep 20117:00 amRNSAnalyst and Investor Site Visit
5th Sep 20117:00 amRNSAppointment of Joint Broker
26th Aug 20117:00 amRNSHalf Yearly Report
10th Aug 20118:58 amRNSHolding(s) in Company
4th Aug 20119:02 amRNSBoard appointment
27th Jul 20111:12 pmRNSHolding(s) in Company
29th Jun 20114:46 pmRNSDirector/PDMR Shareholding
29th Jun 20114:44 pmRNSDirector/PDMR Shareholding
29th Jun 20112:17 pmRNSResult of EGM
22nd Jun 20113:59 pmRNSHolding(s) in Company
16th Jun 20114:39 pmRNSHolding(s) in Company
16th Jun 20114:37 pmRNSHolding(s) in Company
13th Jun 201111:14 amRNSNotice of EGM
9th Jun 201110:44 amRNSHolding(s) in Company
12th May 20113:51 pmRNSResult of AGM
12th May 20117:00 amRNSInterim Management Statement
4th May 20113:17 pmRNSAnnual Information Update
3rd May 20111:30 pmRNSHolding(s) in Company
28th Apr 201112:28 pmRNSHolding(s) in Company
21st Apr 20113:24 pmRNSDirector/PDMR Shareholding
21st Apr 20113:19 pmRNSDirector/PDMR Shareholding
7th Apr 20113:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.